Ticagrelor versus Clopidogrel in Patients with Severe Renal Insufficiency Undergoing PCI for Acute Coronary Syndrome

Table 2

The association between use of different antiplatelet agents and cardiovascular outcomes using an extended cox model.

Outcome	Events (n)		Nonadjusted model		Model I		Model 2
	Ticagrelor (n = 108)	Clopidogrel (n = 168)	HR (95% CI)	value	HR (95% CI)	value	HR (95% CI)	value
Primary end point (composite of CV death, MI and stroke)	39 (36.1)	69 (41.1)	0.83 (0.56∼1.23)	0.353	0.81 (0.50∼1.28)	0.378	0.78 (0.46∼1.33)	0.367
Death from any cause	21 (19.4)	38 (22.6)	0.83 (0.45∼1.55)	0.563	0.86 (0.47∼1.61)	0.645	0.86 (0.38∼1.89)	0.708
Cardiovascular death	15 (13.9)	30 (17.9)	0.72 (0.35∼1.46)	0.356	0.73 (0.36∼1.49)	0.385	0.80 (0.35∼2.12)	0.521
Myocardial infarction	10 (9.3)	23 (13.7)	0.59 (0.25∼1.4)	0.231	0.59 (0.25∼1.4)	0.233	0.72 (0.31∼2.36)	0.485
Ischemic stroke	8 (7.4)	13 (7.7)	0.91 (0.34∼2.46)	0.852	0.94 (0.35∼2.57)	0.909	0.46 (0.24∼3.07)	0.172